Advertisement
Advertisement
ATNM
Actinium Pharmaceuticals, Inc
1.03
USDSponsored
-0.05
-4.63%
Aug 26, 15:34 UTC -4
Open
ATNM Earnings Reports
Positive Surprise Ratio
ATNM beat 25 of 43 last estimates.
58%
Next Report
Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.21
Implied change from Q2 26 (Revenue/ EPS)
-100.00%
/-123.60%
Implied change from Q3 25 (Revenue/ EPS)
-100.00%
/+31.25%
Actinium Pharmaceuticals, Inc earnings per share and revenue
On Aug 07, 2026, ATNM reported earnings of 0.89 USD per share (EPS) for Q2 26, beating the estimate of -0.22 USD, resulting in a 502.71% surprise. Revenue reached 35.00 million, compared to an expected --, with a 0.00% difference. The market reacted with a -3.41% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.21 USD, with revenue projected to reach -- USD, implying an decrease of -123.60% EPS, and decrease of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
CDT Equity Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-Actual
-$8.71
Surprise
-
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
FAQ
What were Actinium Pharmaceuticals, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Actinium Pharmaceuticals, Inc reported EPS of $0.89, beating estimates by 502.71%, and revenue of $35.00M, 0% as expectations.
How did the market react to Actinium Pharmaceuticals, Inc's Q2 2026 earnings?
The stock price moved down -3.41%, changed from $0.80 before the earnings release to $0.77 the day after.
When is Actinium Pharmaceuticals, Inc expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for Actinium Pharmaceuticals, Inc's next earnings report?
Based on 3
analysts, Actinium Pharmaceuticals, Inc is expected to report EPS of -$0.21 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement